

1 **Differences in epidemiology of enteropathogens in children pre- and**
2 **post-rotavirus vaccine introduction in Kilifi, coastal Kenya**

3

4 Charles N. Agoti^{1, 2, #},

5 Martin D. Curran^{3, 4},

6 Nickson Murunga¹,

7 Moses Ngari¹,

8 Ester Muthumbi¹,

9 Arnold Lambisia¹,

10 Simon DW Frost^{5, 6},

11 Barbara Blacklaws⁷,

12 D. James Nokes^{1, 8}, and

13 Lydia N Drumright^{9, 10}

14

15 **Author Affiliations**

16 1. *Epidemiology and Demography Department, KEMRI-Wellcome Trust,*
17 *Kilifi, Kenya.*

18 2. *School of Health and Human Sciences, Pwani University, Kilifi, Kenya.*

19 3. *Public Health England, Cambridge, United Kingdom.*

20 4. *Clinical Microbiology and Public Health Laboratory, Addenbrooke's*
21 *Hospital, Cambridge, United Kingdom.*

22 5. *Microsoft Research, Building 99, 14820 NE 36th St. Redmond, WA 98052,*
23 *USA*

24 6. *Department of Infectious Disease Epidemiology, Faculty of Epidemiology*
25 *and Public Health, London School of Hygiene and Tropical Medicine,*
26 *Keppel St, Bloomsbury, London WC1E 7HT, United Kingdom*

27 7. *Department of Veterinary Medicine, University of Cambridge, Cambridge,*
28 *United Kingdom.*

29 8. *University of Warwick, Coventry, United Kingdom.*

30 9. *Department of Medicine, University of Cambridge, Cambridge, United*
31 *Kingdom.*

32 10. *Department of Medicine, University of Washington, Washington, United*
33 *States*

34

35 #Corresponding author

36 Contact details: P.O. Box 230, Kilifi-80108, Kenya,

37 Email: cnyaigoti@kemri-wellcome.org)

38 **Disclaimers**

39 The views expressed in this article are solely those of the authors and not of
40 the funders or affiliated institutions.

41 **Source (s) of support**

42 This study was supported by the Cambridge-Africa ALBORADA Research
43 Fund.

44

45 **Word Count**

46 Abstract (250): 227

47 Text (3000): 2931

48

49 **Tables & Figures**

50 Tables: 2

51 Figures: 2

52 **Disclosure of relationships and activities**

53 **Key words:** Enteropathogens, RVA, Taqman Array Card, co-infections,
54 Kenya, vaccination, children, epidemiology

55

56 **Running head:**

57 Enteropathogens pre- and post-rotavirus vaccination in Kilifi, Kenya

58

59 **ABSTRACT**

60 **Background.** In July 2014, Kenya introduced the Rotarix® vaccine into its
61 national immunization program. The impact of this vaccination programme on
62 the local epidemiology of enteropathogens is unclear.

63

64 **Methods.** The TaqMan Array Card (TAC) was used for screening for 28
65 different enteropathogens in 718 stools from children less than 13 years of
66 age who presented with diarrhea and were admitted to Kilifi County Hospital,
67 coastal Kenya, in 2013 (before vaccine introduction) and in 2016-2018 (after
68 vaccine introduction). The differences between pre- and post-Rotarix®
69 vaccination periods were examined using univariate and multivariable logistic
70 regressions.

71

72 **Results.** In 665 specimens (92.6%), one or more enteropathogens were
73 detected, while in 323 specimens (48.6%), three or more enteropathogens
74 were detected. There was a significant increase in the proportion of samples
75 containing enteroaggregative *Escherichia coli* (35.7% vs 45.3%, $p=0.014$),
76 cytomegalovirus (4.2% vs 9.9%, $p=0.008$), *Vibrio cholerae* (0.0% vs 2.3%,
77 $p=0.019$), *Strongyloides species* (0.8% vs 3.6%, $p=0.048$) and *Dientamoeba*
78 *fragilis* (2.1% vs 7.8%, $p=0.004$) post-vaccine introduction. Sapovirus
79 detection decreased significantly (7.6% vs 4.0%, $p=0.030$) post-vaccine
80 introduction. The proportion of samples that tested positive for rotavirus group
81 A did not statistically differ between the pre- and post-vaccine periods (27.4%
82 vs. 23.5%, $p=0.253$).

83

84 **Conclusions.** In this setting, the burden of childhood enteropathogen
85 infection was high both pre- and post-rotavirus vaccination introduction, with
86 some specific changes in the burden of enteropathogens in hospitalized
87 children after rotavirus vaccination introduction.

88 INTRODUCTION

89 In 2016, there were approximately 446,000 deaths worldwide caused by
90 diarrheal illnesses among children <5 years, with the majority occurring in low-
91 income countries [1, 2]. Rotavirus group A (RVA) was estimated to be
92 responsible for approximately 128,000 of these deaths.

93

94 The World Health Organization (WHO) recommended inclusion of RVA
95 vaccines in national immunization programs (NIPs) of all countries in 2009.
96 Kenya included Rotarix® vaccination in its National Immunization Program [3]
97 in July 2014, with doses at 6 and 10 weeks of age. Based on antigen testing,
98 Kilifi County Hospital (KCH), Kenya, reported a 57% reduction in rotavirus
99 hospitalizations in the first year after vaccine introduction and an 80%
100 reduction in the second year among children <5 year-olds [4]. KCH found 64%
101 vaccine effectiveness for children aged < 5years [5], which is similar to other
102 low-income settings in sub-Saharan Africa [3, 4], but lower than high-income
103 settings [5, 6].

104

105 Over 30 enteropathogens can cause diarrhea. In addition to a reduction in
106 RVA-induced diarrhea, a referral hospital in Central Kenya observed a 31%
107 decrease in all-cause diarrheal hospital admissions in the first year and a 58%
108 decrease in the second year [7]. While RVA has clearly been responsible for a
109 large burden of severe diarrheal cases among children <5 years-old, many
110 other enteropathogens contribute to severe diarrheal illness in Kenya [8-11]
111 but their epidemiology, both pre- and post-RVA vaccine introduction, is under-
112 studied. Previously, we examined change in prevalence of 5 enteric viruses,
113 including RVA, pre and post RVA vaccination demonstrating an increase in
114 norovirus GII and a decrease in RVA, however this study did not examine all
115 causes of diarrheal illness [12].

116

117 Through the use of a custom TaqMan Array Card (TAC), this study aimed to
118 compare the epidemiological patterns of 28 different enteropathogens in
119 children < 13 years-old admitted to KCH with diarrhea, pre- and post-RVA
120 vaccine introduction.

121

122 **METHODS**

123 **Study design and population.** KCH is a referral facility that primarily serves
124 residents of Kilifi County, Kenya [13]. From September 2009, a surveillance
125 study of rotavirus was established at KCH pediatric ward targeting children
126 <13 years old who presented with diarrhea (defined as passing three or more
127 loose stools in a 24-hour period) [14]. A single stool specimen was collected
128 within 48 hours of admission and immediately put into -4°C before transferring
129 to the adjoining KEMRI-Wellcome Trust Laboratories for long-term storage at
130 -80°C. The current retrospective analysis targeted samples collected in 2013
131 (pre-vaccine period) and 2016-2018 (post-vaccine period). During these
132 periods, sample collection was interrupted 6 times by healthcare worker
133 strikes; 3 times each pre- and post-vaccine introduction [15].

134

135 **Sample processing.** Total nucleic acid was extracted from stool using two
136 different approaches. The *cador* Pathogen 96 QIAcube HT Kit (QIAGEN,
137 Hilden, Germany) with 200 µL liquid or 200 mg solid stool was used on
138 samples from 2013. The QIAamp Fast DNA Stool Mini Kit (QIAGEN, Hilden,
139 Germany) with 200 µL or 200 mg stool after bead-beating and centrifugation
140 to remove debris was used on samples from 2016-2018. An extraction blank
141 was included in every processing batch for quality control. The total nucleic
142 acid extracts (NAE) were stored at -80°C for up to 130 weeks and defrosted
143 once, only for the enteropathogen diagnostics.

144

145 **TaqMan Array Card (TAC) analysis.** A custom TaqMan Array Card (TAC)
146 spotted with lyophilized target-specific primers and probes was used to detect
147 enteropathogens from the total NAE. The GASTRO v4.0K TAC was designed
148 by MC at Public Health England (PHE), Cambridge, England [16] and
149 manufactured by ThermoFisher, USA. GASTRO v4.0K screened for 28
150 enteropathogens: 12 viruses, 10 bacteria, 5 protozoa and 1 helminth
151 (supplementary Table 1). All TAC targets were validated previously by PHE
152 and include 16S bacterial and 18S RNA as internal controls, and
153 bacteriophage MS2 as an external control. A Rotarix[®] vaccine-specific assay
154 targeting the NSP2 gene was included to identify RVA vaccine shedding due
155 to prior vaccination. The molecular probes were labeled at the 5' end with 6-

156 carboxyfluorescein (FAM) reporter dye and NFQ-MGB quencher dye at the 3'
157 end [16].

158

159 For each TAC, 8 samples were tested (48-wells per sample). A mix of 60 µL
160 of nuclease-free water, 25 µL of TaqMan Fast Virus 1-Step MasterMix
161 (ThermoFisher, USA) containing ROX reference dye and 15 µL of NAE was
162 prepared and loaded onto the TAC sample portal. TACs were spun twice at
163 1200 rpm for two minutes and sealed. TACs were processed using the
164 Quantistudio-7-Flex Real-time PCR System (Thermofisher, USA). The
165 thermocycling conditions were; 50°C for 5 minutes followed by 45 cycles of
166 95°C for 1 second and 60°C for 20 seconds. Extraction blanks and no
167 template controls were included once in every 10 runs for quality control.

168

169 Amplification data were analysed by the cycle threshold (Ct) method
170 (QuantiStudio™Real-Time PCR software v.1.1). A threshold value of 0.2
171 florescence units was applied to all our analyses and baseline range set to
172 automatic. The amplification curves for all presumptive positive samples were
173 visually inspected prior to recording them as positive. Pathogen prevalence
174 was evaluated at three different Ct cut-off levels (<40.0, <35.0 and <30.0).

175

176 **Clinical data.** Data were collected using a standard clinical research form
177 (CRF) entered into an electronic database [17]. The CRF included admission
178 date, discharge date, presenting signs and symptoms, co-morbidities, and
179 discharge diagnosis and outcome. Diarrhea was categorized as acute if the
180 duration <7 days, prolonged if 7-13 days, persistent if 14-28 days, and chronic
181 if >28 days. Diarrheal severity was assessed by Vesikari Clinical Severity
182 Score (VCSS) [18]. All samples were clinically tested for rotavirus using a
183 commercial ELISA antigen detection kit (ProsPeCT, Oxoid, Thermo Scientific.
184 All pediatric admissions were offered HIV testing using two rapid antibody
185 tests according to national guidelines.

186

187 **Analyses.** We compared clinical and demographic characteristics of (i)
188 included and excluded children and (ii) those recruited pre- and post-RVA
189 vaccination using chi-squared analysis and Fisher's exact test for categorical

190 variables and Wilcoxon-rank sum and t-tests for continuous variables. As this
191 was the first use of this TAC in Kenya, we descriptively explored different
192 lower limits of detection ($Ct \leq 30, 35, 40$) for a positive result. Using $Ct \leq 35$ as
193 the lower limit of detection, pathogen prevalence was calculated as the
194 proportion positive over the total tested with 95% confidence intervals (CI)
195 calculated using the exact method. We assessed differences in pathogen
196 presence in pre-/post-RVA vaccination periods by univariate logistic
197 regression. Any enteropathogen that was marginally different ($P < 0.1$) in
198 univariate analyses, as well as rotavirus (due to epidemiological interest),
199 were included in multivariable logistic regression analyses adjusted for age,
200 sex, Vesikari score, HIV-status, hospital length of stay (LoS), and fatality.
201 Separate multivariate logistic regression analyses per pathogen were
202 conducted due to the high prevalence of co-infections. The analyses were
203 performed in Stata version 16.1 and R version 3.6.3.

204

205 **Ethical considerations**

206 Before sample collection, informed written consent was gained from each
207 child's parent/guardian. The Scientific and Ethics Review Unit (SERU) at
208 Kenya Medical Research Institute, Nairobi, approved the study protocol
209 (Protocol #3624).

210

211 **RESULTS**

212 **Participant characteristics.** 1,317 KCH pediatric admissions with diarrhea
213 were eligible for inclusion during study periods (2013, 2016-2018). Of these,
214 1250 (95%) were unique patients; 718 (57.4%) provided an adequate stool
215 sample for TAC processing. Children who did and did not have a stool sample
216 were similar except those with a stool sample: (i) were more likely to have
217 reported vomiting at admission ($p=0.001$); (ii) were hospitalized for longer
218 (mean 5.8 days versus 4.3 days, $p < 0.001$); (iii) were more likely to have been
219 discharged alive ($p < 0.001$); (iv) were more likely to have or have been
220 exposed to HIV ($p=0.049$); and (v) were less likely to be included in 2017 and
221 2018 than in 2013 and 2016 ($p < 0.001$) (**Table 1**).

222

223 The children who had provided sufficient stool had a median age of 13.3
224 months (IQR: 8.0-23.0). Clinical and demographic characteristics of children
225 from pre- (2013) and post-vaccine (2016-2018) introduction periods (n=718)
226 were similar except that those from the pre-vaccine period were (i)
227 significantly younger (11.5 vs 14.1 months, p=0.004); (ii) less likely to have
228 known HIV exposure, but more likely to have unknown HIV status (p<0.001);
229 and (iii) had a lower median hospital stay (4 vs 5 days, p=0.005) than those
230 from the post-vaccine period (Table 1).

231

232 **Pathogen prevalence.** Of the 718 specimens analyzed by TAC, using a
233 polymerase chain reaction (PCR) cycle threshold cut-off of ≤ 40.0 Ct (which
234 was considered an appropriate cut-off based on clinical samples from the UK
235 [16, 19]) one or more enteropathogen was detected in 94.0% of the children
236 (n=675). The five most common pathogens at the ≤ 40.0 Ct cut off value were:
237 enteroaggregative *Escherichia coli* (EAggEC) 44.6%; enterovirus 33.0%;
238 enteropathogenic *Escherichia coli* (EPEC) 32.3%; RVA 25.1%; and
239 parechovirus 20.8% (**Figure 1a**). When the limit of detection was lowered to
240 ≤ 30 Ct (high pathogen burden), 12/28 of detected pathogens decreased in
241 prevalence by a factor of 2 or more (**Figure 1c**). The largest declines were
242 observed with verotoxogenic *E. coli* (VTEC) (11 fold), *Dientamoeba fragilis*
243 (8.3 fold), cytomegalovirus (7.4 fold), *Strongyloides spp.* (5.0 fold), *Salmonella*
244 *spp.* (4.0 fold), *Clostridium perfringens/difficile* (3.8 fold) and hepatitis E virus
245 (3.0 fold). Only three pathogens, *D. fragilis*, hepatitis E virus, and VTEC,
246 showed a reduction by factor 2 or more when comparing a Ct value of ≤ 40
247 versus ≤ 35 as the limit of detection. On average, the prevalence of the
248 detected pathogens decreased by 1.3 fold when the Ct cut-off was lowered
249 from 40.0 to 35.0 (**Figure 1b**). Notably, even with the most stringent Ct cut-off
250 (≤ 30), the prevalence of RVA was unaffected: 25.1% (21.9-28.4) at Ct ≤ 40
251 versus 22.3% (19.3-25.5) at Ct ≤ 30 . No samples tested positive for *Vibrio*
252 *parahaemolyticus* and *Entamoeba histolytica* at any Ct detection limit. All
253 subsequent analyses have used the Ct cut-off of ≤ 35.0 for all pathogens.
254 Detection above this threshold has previously been considered clinically
255 insignificant or irreproducible in studies from low-income settings [20, 21].

256

257 **Pathogens pre- and post-vaccine initiation.** Among the 718 samples, 241
258 (33.6%) were from the pre-vaccine period (2013) and 477 (66.4%) were from
259 the post-vaccine introduction period (2016-2018), (**Table 2**). In univariate
260 logistic regression analyses, cytomegalovirus (4.2% vs 9.9%, OR=2.53,
261 $p=0.010$), EA_gEC (35.7% vs 45.3%, OR=1.49, $p=0.009$), *D. fragilis* (2.0% vs
262 7.8%, OR=3.97, $p=0.004$) and *Strongyloides spp.* (0.8% vs 3.6%, OR=4.42,
263 $p=0.048$) all increased in detection from pre- to post-vaccine periods, whereas
264 sapovirus decreased in detection (7.8% vs 4.0%, OR=0.49, $p=0.030$).

265

266 In multivariable models adjusting for age, Vesikari score, fatality, gender,
267 LOS, and HIV-status, cytomegalovirus (OR=2.81, 95% CI 1.36, 5.81),
268 EA_gEC (OR=1.58, 95% CI 1.13, 2.20), *D. fragilis* (OR=3.90, 95% CI 1.49,
269 10.21), and *Strongyloides spp.* (OR=4.60, 95% CI 1.03, 20.55) were all
270 detected among significantly more patients in the post-vaccine than in the pre-
271 vaccine period. Sapovirus no longer demonstrated a significant difference in
272 cases detected after adjusting for covariates (**Table 2**).

273

274 No differences were observed in the prevalence of RVA in the hospitalized
275 children in the pre-post-RVA vaccination time-periods. In sub-analyses of
276 rotavirus infection, receipt of RVA vaccine was not associated with rotavirus
277 infection in multiply adjusted models including age (data not shown). Both lack
278 of reduction in RVA prevalence and lack of association with vaccine status
279 were still consistently observed when restricting analyses to children >5 years
280 old. No significant changes were observed for any of the other remaining
281 pathogens.

282

283 **Co-infections.** Only 53 children (7.4%) had no enteropathogens detected.
284 Among the rest (n=665), 148 (22.3%) were mono-infected, while 323 (48.6%)
285 had ≥ 3 pathogens detected. Including all children, 72% (n=517) had ≥ 2
286 enteropathogens detected. Five or more enteropathogens were detected in 84
287 children (11.7%). A greater number of different enteropathogens were
288 detected per child in the post-vaccine compared to pre-vaccine period (mean:
289 2.7 vs 2.3 respectively, $p=0.0025$).

290

291 **Characteristics of rotavirus positive samples.** The distribution of Ct values
292 for RVA positive samples based on the TAC analysis is shown in Figure 2, in
293 relation to (a) previous RVA ELISA test result, (b) sample period, (c)
294 vaccination status, and (d) age group. We found that the median Ct values
295 among older children are significantly lower than those among younger
296 children, regardless of the sampling year.

297

298 **DISCUSSION**

299 Our study shows very high prevalence of enteropathogens among
300 hospitalized children with diarrhea, extensive co-infections, and differences in
301 pathogen prevalence before and after rotavirus vaccine introduction. In
302 addition, we observed no significant difference in RVA prevalence between
303 pre- and post-vaccine introduction.

304

305 The Global Rotavirus Surveillance Network showed that RVA prevalence
306 decreased in children under 5 years of age from 2008 and 2016 following
307 national introduction of the RVA vaccine across 82 countries, although to a
308 lesser extent among low-income countries [24]. Using controlled interrupted
309 time series analysis, >50% decline in RVA cases were observed in two sites
310 in Kenya following Rotarix® introduction [22]. One of these sites was KCH. In
311 a previous analysis, using different viral detection assays, we also observed a
312 reduction in RVA among children <5 years old [12]. Our study did not find any
313 reduction in RVA prevalence among KCH children; however, there were some
314 key differences between our study and the previous studies. First, to detect
315 RVA infection, we used a TAC, which is considerably more sensitive than the
316 immunoassay (EIA) used in other studies [23]. Secondly, our study included
317 children up to 13 years of age, whereas the other studies included only
318 children under 5. In the previous Kenyan studies, children were sampled
319 between 2014 and 2017 [22] and 2003, 2013, 2016, and 2019 [12], which
320 does not overlap entirely with our study. The inclusion of older children and
321 the use of TAC provide evidence of a general prevalence of RVA in children,
322 as opposed to only the vaccine eligible children [24].

323

324 The most frequently detected enteropathogens in our study in descending
325 order were; EAggEC, EPEC, enterovirus, RVA, parechovirus, Norovirus,
326 *Cryptosporidium spp.*, *Shigella spp.* and *Giardia lamblia*. In the Global Enteric
327 Multicenter Study of children <5 years-old, the most common pathogens
328 associated with diarrheal illness were RVA, enterotoxigenic *E. coli*,
329 *Cryptosporidium spp.*, *H. pylori*, norovirus GII, *Aeromonas spp.*, adenovirus,
330 EPEC, *Shigella spp.*, *C. difficile*, and sapovirus [25]. Similarly, a study of
331 bacterial diarrheal infections in <5 year-olds in Western Kenya revealed that
332 *E. coli* and *Shigella* were the most common bacterial infections [26]. Our
333 previous study only examining a handful of viral pathogens among children <5
334 years at KCH demonstrated low prevalence of viral infections, with RVA and
335 adenovirus being the most common [12]. Although these studies took place in
336 different geographic regions and/or used different methods of pathogen
337 detection than ours, there is still consistency in the types of enteropathogens
338 observed.

339

340 There have been a very few studies focusing on changes in multiple
341 enteropathogen presentation after rotavirus vaccination [14, 22, 27-33]. We
342 observed a significant increase in prevalence of cytomegalovirus, EAggEC, *D.*
343 *fragilis* and *Strongyloides spp.* post-vaccination, as well as an increase in
344 enteropathogen co-infection, suggesting that a reduction in RVA could result
345 in a greater opportunity for other enteropathogens to fill the ecological niche
346 previously occupied by RVA. Interestingly, a study among hospitalized
347 children <5 years old in Tanzania examining the etiology of diarrheal illness
348 post-rotavirus vaccine found RVA, ETEC, *Shigella*, *Cryptosporidium spp.* and
349 astrovirus to be the five leading causes of diarrhea [34].

350

351 We demonstrated both a significant increase in prevalence of specific
352 enteropathogens as well as co-infection following introduction of the rotavirus
353 vaccine. While the detected enteropathogens could cause the diarrhea
354 observed in these hospitalized children, it is unclear which are symptomatic
355 illness versus long-term carriage. In order to understand changes in both
356 burden and disease following RVA vaccine introduction, repeated measures
357 studies on the same individuals including community controls are necessary.

358 Such studies will also be important in understanding the longer-term impact of
359 vaccination, carriage, and infection on children in LMIC settings.

360

361 This study had some limitations. Samples were collected more than two years
362 prior to analysis, which could compromise sample integrity. This setting might
363 have experienced a further change in enteropathogen burden since 2018 in
364 part due to the COVID-19 pandemic. However, this does not invalidate the
365 hypotheses generated by the findings regarding enteropathogen dynamics,
366 but rather suggests that continuous surveillance is critical for adapting and
367 maximizing diarrheal illness prevention. We did not analyze healthy controls
368 to adjust for the background prevalence of the detected enteropathogens in
369 this population. Of eligible children, 56.9% provided samples, which limited
370 our ability to assess the entire population of hospitalised children with
371 diarrhea. As a result of health worker industrial action in Kenya, enrollment
372 was interrupted five times [15]. In the pre-vaccine and post-vaccine
373 introduction years, the total nucleic acid extraction procedure varied, but we
374 did not expect this to have significantly impacted enteropathogen prevalence.
375 In spite of previous studies finding an association between pathogen
376 quantities and diarrhea attribution, we did not attempt to model these
377 associations in this study [21]. Finally, given the unbalanced time series
378 nature of this study it is difficult to draw conclusions about enteropathogen
379 dynamics following rotavirus vaccine introduction.

380

381 This study demonstrated increases in prevalence of EAEC, cytomegalovirus,
382 *D. fragilis*, *Strongyloides spp.* and co-infections post-rotavirus vaccination, but
383 little decrease in rotavirus infections in hospitalized children. Furthermore, we
384 observed increased detection of RVA by TAC compared to ELISA. These
385 findings highlight the need to use multiple detection arrays, such as TAC, for
386 regular surveillance of hospitalized children and community controls in order
387 to develop our understanding of differential observations of rotavirus vaccine
388 efficacy in settings with different RVA prevalence in order to tailor the best
389 vaccine approaches. Furthermore, such studies would provide insight into the
390 clinical implications of the frequent co-infections among children in order to
391 support high-quality interventions and individual patient care. Finally, our

392 study suggests the need for broad diagnostic approaches with high sensitivity
393 and specificity for enteropathogen surveillance and assessment of
394 enteropathogen vaccination efficacy.

395

396 **Acknowledgement.** We thank the study participants who provided the
397 samples and members of the Virus Epidemiology and Control (VEC) group at
398 KEMRI-Wellcome Trust Programme who collected the samples and
399 performed the laboratory processing. We thank Prof. Philip Bejon for
400 stimulating discussions about the work and comment provided on the initial
401 draft manuscript. This study is published with permission from Director
402 KEMRI.

403

404 **Funding.** This study was funded by the Cambridge-Africa ALBORADA
405 Research Fund . Dr Charles Agoti was supported by the Initiative to Develop
406 African Research Leaders (IDeAL) through the DELTAS Africa Initiative [DEL-
407 15-003]. The DELTAS Africa Initiative is an independent funding scheme of
408 the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence
409 in Science in Africa (AESA) and supported by the New Partnership for Africa's
410 Development Planning and Coordinating Agency (NEPAD Agency). Dr Lydia
411 Drumright was supported by the following funding sources during this study:
412 Medical Research Council (award # MR/S013164/1), the Alan Turing Institute
413 through a Research Fellowship, the National Institutes for Health Research
414 (award # CDF-2011-04-017) and the Cambridge Biomedical Research
415 Center, the Economic and Social Science Research Council (award #
416 AH/R001952/1), and an Isaac Newton/Wellcome Trust ISSF award to
417 understand gastrointestinal infection epidemiology through use of this TAC.
418 The views expressed in this report are those of the authors and not
419 necessarily those of AAS, NEPAD Agency, The Wellcome, the UK
420 government.

421

422 **Data availability**

423 The data described in this manuscript can be accessed by submitting a
424 request form to our Data Governance Committee ([http://kemri-
425 wellcome.org/about-us/#ChildVerticalTab_15](http://kemri-wellcome.org/about-us/#ChildVerticalTab_15)).

426

427 **REFERENCES:**

- 428 1. Troeger C, Blacker BF, Khalil IA, et al. Estimates of the global, regional, and
429 national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a
430 systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*
431 *Infectious Diseases* **2018**; 18:1211-28.
- 432 2. Rogawski ET, Liu J, Platts-Mills JA, et al. Use of quantitative molecular diagnostic
433 methods to investigate the effect of enteropathogen infections on linear growth in
434 children in low-resource settings: longitudinal analysis of results from the MAL-ED
435 cohort study. *Lancet Glob Health* **2018**; 6:e1319-e28.
- 436 3. Steele AD, Victor JC, Carey ME, et al. Experiences with rotavirus vaccines: can we
437 improve rotavirus vaccine impact in developing countries? *Human Vaccines &*
438 *Immunotherapeutics* **2019**; 15:1215-27.
- 439 4. Murunga N, G PO, Maia M, C NA. Effectiveness of Rotarix (®) vaccine in Africa in
440 the first decade of progressive introduction, 2009-2019: systematic review and
441 meta-analysis. *Wellcome Open Res* **2020**; 5:187.
- 442 5. Willame C, Vonk Noordegraaf-Schouten M, Gvozdenovic E, et al. Effectiveness of
443 the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-
444 analysis-2006-2016. *Open Forum Infect Dis* **2018**; 5:ofy292.
- 445 6. Walker JL, Andrews NJ, Atchison CJ, et al. Effectiveness of oral rotavirus
446 vaccination in England against rotavirus-confirmed and all-cause acute
447 gastroenteritis. *Vaccine X* **2019**; 1:100005.
- 448 7. Wandera EA, Mohammad S, Bundi M, et al. Impact of rotavirus vaccination on
449 rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. *Vaccine* **2017**;
450 35:5217-23.
- 451 8. Omore R, Khagayi S, Ogwel B, et al. Rates of hospitalization and death for all-cause
452 and rotavirus acute gastroenteritis before rotavirus vaccine introduction in Kenya,
453 2010–2013. *BMC Infectious Diseases* **2019**; 19:47.
- 454 9. Swierczewski BE, Odundo EA, Koech MC, et al. Surveillance for enteric pathogens
455 in a case-control study of acute diarrhea in Western Kenya. *Trans R Soc Trop Med*
456 *Hyg* **2013**; 107:83-90.
- 457 10. Njuguna C, Njeru I, Mgamb E, et al. Enteric pathogens and factors associated with
458 acute bloody diarrhoea, Kenya. *BMC Infect Dis* **2016**; 16:477.
- 459 11. Florez ID, Niño-Serna LF, Beltrán-Arroyave CP. Acute Infectious Diarrhea and
460 Gastroenteritis in Children. *Current Infectious Disease Reports* **2020**; 22.
- 461 12. Lambisia AW, Onchaga S, Murunga N, Lewa CS, Nyanjom SG, Agoti CN.
462 Epidemiological Trends of Five Common Diarrhea-Associated Enteric Viruses Pre- and
463 Post-Rotavirus Vaccine Introduction in Coastal Kenya. *Pathogens* **2020**; 9.
- 464 13. Scott JA, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic
465 Surveillance System (KHDSS). *Int J Epidemiol* **2012**; 41:650-7.
- 466 14. Khagayi S, Omore R, Otieno GP, et al. Effectiveness of Monovalent Rotavirus
467 Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan
468 Children. *Clin Infect Dis* **2020**; 70:2298-305.
- 469 15. Ong'ayo G, Ooko M, Wang'ondur R, et al. Effect of strikes by health workers on
470 mortality between 2010 and 2016 in Kilifi, Kenya: a population-based cohort
471 analysis. *Lancet Glob Health* **2019**; 7:e961-e7.

- 472 16. Marongiu L, Shain E, Drumright L, Lillestøl R, Somasunderam D, Curran MD.
473 Analysis of TaqMan Array Cards Data by an Assumption-Free Improvement of the
474 maxRatio Algorithm Is More Accurate than the Cycle-Threshold Method. *PLOS ONE*
475 **2016**; 11:e0165282.
- 476 17. Talbert A, Ngari M, Bauni E, et al. Mortality after inpatient treatment for diarrhea
477 in children: a cohort study. *BMC Medicine* **2019**; 17.
- 478 18. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical
479 scores for clinical severity of diarrhoeal episodes. *Scand J Infect Dis* **1990**; 22:259-67.
- 480 19. Heaney J, Rolfe K, Gleadall NS, Greatorex JS, Curran MD. Low-Density TaqMan®
481 Array Cards for the Detection of Pathogens. *Methods in Microbiology* **2015**; 42:199-
482 218.
- 483 20. Iturriza-Gómara M, Jere KC, Hungerford D, et al. Etiology of Diarrhea Among
484 Hospitalized Children in Blantyre, Malawi, Following Rotavirus Vaccine Introduction:
485 A Case-Control Study. *The Journal of Infectious Diseases* **2019**; 220:213-8.
- 486 21. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic
487 methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-
488 control study. *Lancet* **2016**; 388:1291-301.
- 489 22. Otieno GP, Bottomley C, Khagayi S, et al. Impact of the Introduction of Rotavirus
490 Vaccine on Hospital Admissions for Diarrhea Among Children in Kenya: A Controlled
491 Interrupted Time-Series Analysis. *Clin Infect Dis* **2020**; 70:2306-13.
- 492 23. Moutelíková R, Dvořáková Heroldová M, Holá V, Sauer P, Prodělalová J. Human
493 rotavirus A detection: Comparison of enzymatic immunoassay and rapid
494 chromatographic test with two quantitative RT-PCR assays. *Epidemiol Mikrobiol*
495 *Imunol* **2018**; 67:110-3.
- 496 24. Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing
497 rotavirus diarrhoea: vaccines in use. *Cochrane Database Syst Rev* **2012**;
498 11:Cd008521.
- 499 25. Kotloff KL, Nasrin D, Blackwelder WC, et al. The incidence, aetiology, and adverse
500 clinical consequences of less severe diarrhoeal episodes among infants and children
501 residing in low-income and middle-income countries: a 12-month case-control study
502 as a follow-on to the Global Enteric Multicenter Study (GEMS). *Lancet Glob Health*
503 **2019**; 7:e568-e84.
- 504 26. RonoSalinah J, Rose K, Fabian E. Prevalence and clinico-demographic
505 characteristics associated with bacterial diarrhea among HIV positive and negative
506 children aged below five years at Moi Teaching and Referral Hospital, Kenya.
507 *American Journal of Life Sciences* **2014**; 2:1-8.
- 508 27. Aliabadi N, Antoni S, Mwenda JM, et al. Global impact of rotavirus vaccine
509 introduction on rotavirus hospitalisations among children under 5 years of age,
510 2008-16: findings from the Global Rotavirus Surveillance Network. *Lancet Glob*
511 *Health* **2019**; 7:e893-e903.
- 512 28. Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar UD. Global Impact of Rotavirus
513 Vaccination on Childhood Hospitalizations and Mortality From Diarrhea. *J Infect Dis*
514 **2017**; 215:1666-72.
- 515 29. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on
516 childhood deaths from diarrhea in Brazil. *Int J Infect Dis* **2011**; 15:e206-10.
- 517 30. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world
518 impact of rotavirus vaccination. *Pediatr Infect Dis J* **2011**; 30:S1-5.

- 519 31. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel
520 MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among
521 children < 5 years of age in Mexico. *Pediatr Infect Dis J* **2011**; 30:S11-5.
522 32. Msimang VM, Page N, Groome MJ, et al. Impact of rotavirus vaccine on
523 childhood diarrheal hospitalization after introduction into the South African public
524 immunization program. *Pediatr Infect Dis J* **2013**; 32:1359-64.
525 33. Weldegebriel G, Mwenda JM, Chakauya J, et al. Impact of rotavirus vaccine on
526 rotavirus diarrhoea in countries of East and Southern Africa. *Vaccine* **2018**; 36:7124-
527 30.
528 34. Platts-Mills JA, Amour C, Gratz J, et al. Impact of Rotavirus Vaccine Introduction
529 and Postintroduction Etiology of Diarrhea Requiring Hospital Admission in Haydom,
530 Tanzania, a Rural African Setting. *Clin Infect Dis* **2017**; 65:1144-51.
531

TABLES

Table 1. Demographic and clinical characteristics of the eligible, included and excluded participants and, among participants, pre-vaccine versus the post-vaccine introduction period comparisons.

Characteristic	All eligible (n=1250) n (%)	Included (n=718) n (%)	Excluded* (n=532) n (%)	Included vs Excluded p-value	Pre-vaccine (n=241) n (%)	Post-vaccine (n=477) n (%)	Pre- vs Post- Vaccine p-value
Sex (Male)	697 (55.8)	402 (56.0)	295 (55.5)	0.0850	139 (57.7)	263 (55.1)	0.517
Median age (IQR) <i>in months</i>	13.8 (8.2-24.6)	13.3 (8.0-23.0)	14.3 (8.5-26.6)	0.081	11.5 (6.8-21.5)	14.1 (8.5-24.2)	0.004
Age category (in months)				0.115			0.050
0-11	528 (42.2)	323 (45.0)	205 (38.5)		126 (52.3)	197 (41.3)	
12-23	402 (32.2)	224 (31.2)	178 (33.5)		65 (27.0)	159 (33.3)	
24-59	203 (16.2)	106 (14.8)	97 (18.2)		31 (12.9)	75 (15.7)	
>60	117 (9.4)	65 (9.1)	52 (9.8)		19 (7.9)	46 (9.6)	
Admission year				<0.001			
Year 2013	351 (28.1)	241 (33.6)	110 (20.7)		241 (100.0)	-	NA
Year 2016	348 (27.8)	245 (34.1)	103 (19.4)		-	252 (51.4)	
Year 2017	196 (15.7)	61 (8.5)	135 (25.4)		-	641(12.8)	
Year 2018	355 (28.4)	171 (23.8)	184 (34.6)		-	171 (35.9)	
HIV status				0.049			<0.001
Negative	994 (79.5)	565 (78.7)	429 (80.6)		171 (71.0)	394 (82.6)	
Infected/exposed	78 (6.24)	55 (7.7)	23 (4.3)		14 (5.8)	41 (8.6)	
Unknown	178 (14.2)	98 (13.7)	80 (15.0)		56 (23.2)	42 (8.8)	
Diarrhoea history at admission				0.497			0.371
Acute	1130 (90.4)	657 (91.5)	473 (88.9)		222 (92.1)	435 (91.2)	
Prolonged	79 (6.3)	40 (5.6)	39 (7.3)		10 (4.2)	30 (6.3)	
Persistent	10 (0.8)	5 (0.7)	5 (0.9)		3 (1.2)	2 (0.4)	
Chronic	31 (2.5)	16 (2.2)	16 (2.2)		6 (2.5)	10 (2.1)	
Bloody diarrhoea (n=1245)	75 (6.0)	42 (5.9)	33 (6.2)	0.796	17 (7.1)	25 (5.3)	0.328
Vomiting at admission	817 (65.4)	498 (69.4)	319 (60.0)	0.001	171 (71.0)	327(68.6)	0.510
Hospital length of stay							
Mean (SD#)	5.2 (5.0)	5.8 (5.4)	4.3 (4.3)	<0.001	5.5 (5.5)	5.9 (5.3)	0.317
Median (IQR)	4 (2-6)	4 (3-7)	3 (1-6)	<0.001	4 (2-7)	5 (3-7)	0.005
Vesikari Clinical Severity Score							
Mean (SD#)	11.4 (2.3)	11.5 (2.3)	11.3 (2.3)	0.183	11.7 (2.5)	11.4 (2.1)	0.062
Median (IQR)	11 (10-13)	11 (10-13)	11 (10-13)	0.182	11 (10-13)	11 (10-13)	0.289
Died before discharge	145 (11.6)	39 (5.4)	106 (19.9)	<0.001	8 (3.2)	31 (6.5)	0.076

* Due to insufficient stool sample provision

Table 2. Univariate and multivariate logistic regression comparing enteropathogen infection in the pre- vs post-rotavirus vaccine introduction periods (n=718)

Pathogen Type	Pathogen	Prevalence				Univariate Logistic Regression		Multivariable [#] Logistic Regression		
		Total (n=718) n (%)	Pre-vaccine (n=241) # +ve cases	Proportion (95% CI)	Post-vaccine (n=477) # +ve cases	Proportion (95% CI)	OR (95% CI)	p value	OR (95% CI)	p value
Virus	Adenovirus 40/41	49 (6.8)	14	5.8 (3.2-9.6)	35	7.3 (4.2-10.1)	1.28 (0.68, 2.44)	0.444	1.16 (0.60, 2.24)	0.667
	Any Adenovirus	104 (14.5)	28	11.6 (7.9-16.4)	76	15.9 (12.8-19.5)	1.44 (0.91, 2.29)	0.122	1.33 (0.82, 2.13)	0.247
	Rotavirus group A	178 (24.8)	66	27.4 (21.9-33.5)	112	23.5 (19.8-27.6)	0.81 (0.57, 1.16)	0.253	0.97 (0.66, 1.42)	0.879
	Norovirus GI/GII	103 (14.4)	27	11.2 (7.5-15.9)	76	15.9 (12.8-19.5)	1.50 (0.94, 2.40)	0.089	1.53 (0.94, 2.49)	0.086
	Astrovirus	34 (4.7)	12	5.0 (2.6-8.5)	22	4.6 (2.9-7.0)	0.81 (0.57, 1.16)	0.253	0.97 (0.66, 1.42)	0.879
	Sapovirus	38 (5.3)	19	7.6 (4.8-1.0)	19	4.0 (2.4-6.2)	0.49 (0.25, 0.93)	0.030	0.64 (0.32, 1.28)	0.205
	Enterovirus	19 (26.9)	65	27.0 (21.5-33.0)	128	26.8 (23.0-31.1)	0.99 (0.70, 1.41)	0.969	0.97 (0.67, 1.39)	0.851
	Parechovirus	119 (16.6)	47	19.5 (14.7-25.1)	72	15.1 (12.0-18.6)	0.73 (0.49, 1.10)	0.135	0.73 (0.48, 1.12)	0.158
	Hepatitis A virus	11 (1.5)	1	0.4 (0.0-2.3)	10	2.0 (1.0-3.8)	5.14 (0.65, 40.38)	0.120	4.00 (0.50, 31.77)	0.190
	Hepatitis E virus	1 (0.14)	0	0 (0-1.5)	1	0.2 (0.0-1.2)	NA		NA	
Bacteria	Cytomegalovirus	57 (7.9)	10	4.2 (2.0-7.5)	47	9.9 (7.3-12.9)	2.53 (1.25, 5.09)	0.010	2.81 (1.36, 5.81)	0.005
	Enteropathogenic <i>E. coli</i>	217 (30.2)	68	28.2 (22.6-34.4)	149	31.2 (27.1-35.6)	1.16 (0.82, 1.63)	0.405	1.24 (0.87, 1.76)	0.240
	Enterococcal <i>E. coli</i>	302 (42.1)	86	35.7 (29.6-42.1)	216	45.3 (40.8-50.0)	1.49 (1.08, 2.05)	0.014	1.58 (1.13, 2.20)	0.007
	Verotoxigenic <i>E. coli</i>	4 (0.6)	0	0 (0-1.5)	4	0.8 (0.2-2.1)	NA	0.176	NA	
	<i>Shigella spp</i>	83 (11.6)	21	8.7 (5.5-13.0)	62	13.0 (10.2-16.4)	1.57 (0.93, 2.64)	0.092	1.49 (0.87, 2.54)	0.144
	<i>C. perfringens/difficile</i>	33 (4.6)	8	3.3 (1.4-6.4)	25	5.2 (3.4-7.6)	1.61 (0.72, 3.63)	0.250	1.51 (0.66, 3.47)	0.334
	<i>Salmonella spp</i>	15 (2.1)	5	2.0 (0.7-4.8)	10	2.1 (1.0-3.8)	1.01 (0.34, 2.99)	0.985	1.10 (0.35, 3.42)	0.877
	<i>C. jejuni/coli</i>	56 (7.8)	17	7.1 (4.2-11.1)	39	8.2 (5.9-11.0)	1.17 (0.65, 2.12)	0.597	1.13 (0.61, 2.07)	0.706
	<i>V. cholerae</i>	11 (1.53)	0	0 (0-1.5)	11	2.3 (1.2-4.1)	NA		NA	
	<i>Aeromonas spp</i>	7 (1.0)	3	1.3 (0.3-3.6)	4	0.8 (0.2-2.1)	0.67 (0.15, 3.02)	0.603	0.74 (0.15, 3.56)	0.707
<i>Y. enterocolitica</i>	2 (0.3)	0	0 (0-1.5)	2	0.3 (0.0-1.5)	NA		NA		
Protozoa	<i>Cryptosporidium spp</i>	98 (13.7)	28	11.6 (7.9-16.4)	70	14.7 (11.6-18.2)	1.31 (0.82, 2.09)	0.261	1.36 (0.83, 2.20)	0.219
	<i>D. fragilis</i>	42 (5.9)	5	2.0 (0.7-4.8)	37	7.8 (5.5-10.5)	3.97 (1.54, 10.23)	0.004	3.90 (1.49, 10.21)	0.006
	<i>G. lamblia</i>	81 (11.3)	27	11.2 (7.5-15.9)	54	11.3 (8.6-14.5)	1.01 (0.62, 1.65)	0.963	0.96 (0.57, 1.61)	0.881
	<i>C. belli</i>	1 (0.14)	0	0 (0-1.5)	1	0.4 (0.0-1.2)	NA		NA	
	<i>C. cayetanensis</i>	2 (0.3)	2	0.8 (0.1-3.0)	0	0.0 (0.0-0.7)	NA	0.110	NA	
Helminth	<i>Strongyloides spp.</i>	19 (2.7)	2	0.8 (0.1-3.0)	17	3.6 (2.1-5.7)	4.42 (1.01, 19.27)	0.048	4.60 (1.03, 20.55)	0.046

All models are adjusted for age, vesikari score, fatality, length of stay (LOS), HIV status, and gender; due to high coinfection rates, enteropathogens are modelled separately.

FIGURES LEGENDS

Figure 1. Prevalence of enteropathogens in stool samples from 718 children hospitalised at KCH at different PCR cycle threshold (Ct) cut-offs. The bars represent organism type and include 95% confidence interval errors bars for the proportions. Panel (a) prevalence of the detected enteropathogens when applying a Ct cut-off of ≤ 40 to define positives. Panel (b) prevalence of the detected enteropathogens when applying a Ct cut-off ≤ 35 to define positives. Panel (c) prevalence of detected the enteropathogens when applying a Ct cut-off ≤ 30 to define positives.

Figure 2. Boxplots examining the relationship between the observed RVA detection cycle threshold (Ct) from TAC assay and (a) previous enzyme-linked immunosorbent assay (ELISA) result on the same samples, (b) period of sample collection, (c) rotavirus vaccination status, and (d) age group in stool samples from 718 children at KCH. P-values are derived from an independent t-test, one-way ANOVA, and where applicable Kruskal Wallis was used.

Figure 1.




Figure 2.

